Ionis Pharmaceuticals (IONS) Earnings Expected to Grow: What to Know Ahead of Next Week's ReleaseZacks Investment Research • 02/17/22
Pfizer (PFE) Ends Vupanorsen Development, Returns Rights to IonisZacks Investment Research • 02/01/22
BofA Downgrades Ionis After Vupanorsen Setback: Are There Upcoming Catalysts That Can Help The Stock?Benzinga • 02/01/22
Pfizer and Ionis announce discontinuation of vupanorsen clinical development programPRNewsWire • 01/31/22
Moore Kuehn, PLLC Encourages Investors of Ionis Pharmaceuticals, Inc. to Contact Law FirmNewsfile Corp • 01/21/22
Ionis strengthens leadership team with appointments of Joseph Baroldi as chief business officer and Eric Bastings, M.D., as vice president, development strategyPRNewsWire • 01/19/22
Ionis' partner to evaluate tominersen for Huntington's disease in new Phase 2 trialPRNewsWire • 01/18/22
Biogen Exercises Option with Ionis to Develop and Commercialize Investigational ASO for SMAPRNewsWire • 01/04/22
Ionis, AstraZeneca Ink Licensing Pact For Eplontersen In Protein Misfolding DisorderBenzinga • 12/07/21
Ionis Pharmaceuticals (IONS) Down 24.5% Since Last Earnings Report: Can It Rebound?Zacks Investment Research • 12/03/21